BioConvergence for Health (BioConvS) is a major research and innovation area (DIM) of the Île-de-France Region which aims to structure communities of researchers in synthetic biology, biotherapy and bioproduction, to support the transition of scientific excellence towards innovation, and position the Île-de-France Region as an international reference in the field.
BioConvS is led by Université Paris Cité in partnership with Sorbonne Université, Institut Curie - PSL, Institut Micalis (INRAe, AgroParisTech, Université Paris-Saclay), INSERM, Généthon, Génopole and others. BioConvS brings together actors from the public and private sectors and benefits from €12.5 million in support from the Île de France Region. More details on DIM BioConvS at: https://bioconvs.org/
About the 2023 II equipment call
This DIM BioconvS equipment AAP is open from October 9, 2023 to January 31, 2024 and devotes a total budget of €675,000 to finance the purchase of equipment. The equipment will be financed by the Île-de-France Region with a maximum intervention rate of 66% of expenses excluding tax. A co-financing of 34% must therefore be justified in the financing request.
You can submit a single request per principal investigator for the financing of equipment whose total cost must amount to at least €7,500 (therefore for a grant of at least €4,950).
The amount of the subsidy decided by the DIM is a maximum amount: actual expenses (on presentation of invoices) are subsidized up to the intervention rate up to the total amount of the subsidy. For example, if the actual expenses presented for equipment are €37,879 excluding tax with an intervention rate of 66%, the amount of the subsidy will be €25,000.
Loading... 
